These approaches are truly ground-breaking endeavors and as of now, only a few life sciences companies are piloting them and none to few have implemented them. However, with advent of generative AI, there is a potential for accelerating the development of highly sophisticated systems, which will impact all stages of a drug or device life cycle. Let alone communication strategies, organizations can prepare for a future where clinical research itself will be expedited and outcomes data and messages will be made available to communications teams at a much faster pace.